Regulatory efforts to address the access gap for foreign new drugs in China: the priority review program and related policies
{{output}}
Background: China has implemented the priority review (PR) program and flexible registration requirements for new drugs with significant clinical value since 2016 to accelerate drug access. We aim to explore the impact of the ref... ...
